These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26418900)

  • 1. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
    Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
    Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.
    He J; Shi XY; Li ZM; Pan XH; Li ZL; Chen Y; Yan SJ; Xiao L
    BMC Mol Cell Biol; 2019 Nov; 20(1):49. PubMed ID: 31718559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
    Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
    Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer.
    Song T; Jeon HK; Hong JE; Choi JJ; Kim TJ; Choi CH; Bae DS; Kim BG; Lee JW
    Cancer Res Treat; 2017 Jul; 49(3):595-606. PubMed ID: 27669706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma.
    Han HD; Cho YJ; Cho SK; Byeon Y; Jeon HN; Kim HS; Kim BG; Bae DS; Lopez-Berestein G; Sood AK; Shin BC; Park YM; Lee JW
    Mol Cancer Ther; 2016 Apr; 15(4):618-27. PubMed ID: 26861249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
    Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
    Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
    Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
    Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
    Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
    Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
    Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors may reduce tumour resistance.
    De Milito A; Fais S
    Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
    Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
    Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
    Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
    Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.